{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T03:43:22Z","timestamp":1792035802544,"version":"4.4.0"},"reference-count":112,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2019,12,1]],"date-time":"2019-12-01T00:00:00Z","timestamp":1575158400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,12,1]],"date-time":"2019-12-01T00:00:00Z","timestamp":1575158400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2019,12,17]],"date-time":"2019-12-17T00:00:00Z","timestamp":1576540800000},"content-version":"vor","delay-in-days":16,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Pharmacology"],"published-print":{"date-parts":[[2019,12]]},"DOI":"10.1016\/j.ejphar.2019.172747","type":"journal-article","created":{"date-parts":[[2019,10,18]],"date-time":"2019-10-18T11:59:17Z","timestamp":1571399957000},"page":"172747","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":42,"special_numbering":"C","title":["Selected nucleos(t)ide-based prescribed drugs and their multi-target activity"],"prefix":"10.1016","volume":"865","author":[{"given":"Gabriela","family":"Pastuch-Gawo\u0142ek","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Danuta","family":"Gillner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ewelina","family":"Kr\u00f3l","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Krzysztof","family":"Walczak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ilona","family":"Wandzik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejphar.2019.172747_bib1","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1177\/095632029100200306","article-title":"Antiviral activity against VZV and HSV type 1 and type 2 of the (+) and (-) enantiomers of (R,S)-9-[4-hydroxy-2-(hydroxymethyl)butyl]guanine, in comparison to other closely related acyclic nucleosides","volume":"2","author":"Abele","year":"1991","journal-title":"Antivir. Chem. Chemother."},{"key":"10.1016\/j.ejphar.2019.172747_bib2","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/j.pharmthera.2018.02.006","article-title":"Nucleosidic DNA demethylating epigenetic drugs \u2013 a comprehensive review from discovery to clinic","volume":"188","author":"Agrawal","year":"2018","journal-title":"Pharmacol. Ther."},{"key":"10.1016\/j.ejphar.2019.172747_bib3","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1081\/NCN-100002508","article-title":"6-Azacytidine \u2013 compound with wide spectrum of antiviral activity","volume":"20","author":"Alexeeva","year":"2001","journal-title":"Nucleosides Nucleotides Nucleic Acids"},{"key":"10.1016\/j.ejphar.2019.172747_bib4","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1080\/15257770.2015.1034363","article-title":"Synthesis and comparative study of anti-adenoviral activity of 6-azacytidine and its analogues","volume":"34","author":"Alexeeva","year":"2015","journal-title":"Nucleosides Nucleotides Nucleic Acids"},{"key":"10.1016\/j.ejphar.2019.172747_bib5","doi-asserted-by":"crossref","first-page":"1081","DOI":"10.1128\/AAC.49.3.1081-1086.2005","article-title":"Susceptibilities of several clinical varicella-zoster virus (VZV) isolates and drug-resistant VZV strains to bicyclic furano pyrimidine nucleosides","volume":"49","author":"Andrei","year":"2005","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.ejphar.2019.172747_bib6","doi-asserted-by":"crossref","first-page":"2641","DOI":"10.1128\/JVI.06620-11","article-title":"In vitro-selected drug-resistant varicella-zoster virus mutants in the thymidine kinase and DNA polymerase genes yield novel phenotype-genotype Associations and highlight differences between antiherpesvirus drugs","volume":"86","author":"Andrei","year":"2012","journal-title":"J. Virol."},{"key":"10.1016\/j.ejphar.2019.172747_bib7","series-title":"Mandell, Douglas, and Bennett's Principles and Practice of Infectious Diseases","article-title":"Antivirals against herpes viruses","author":"Aoki","year":"2015"},{"key":"10.1016\/j.ejphar.2019.172747_bib8","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.coviro.2017.03.009","article-title":"Direct-acting antivirals and host-targeting strategies to combat enterovirus infections","volume":"24","author":"Bauer","year":"2017","journal-title":"Curr. Opin. Virol."},{"key":"10.1016\/j.ejphar.2019.172747_bib9","doi-asserted-by":"crossref","first-page":"2778","DOI":"10.1099\/vir.0.069864-0","article-title":"Novel inhibitors of human immunodeficiency virus type 2 infectivity","volume":"95","author":"Beach","year":"2014","journal-title":"J. Gen. Virol."},{"key":"10.1016\/j.ejphar.2019.172747_bib10","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0030286","article-title":"Cellular growth kinetics distinguish a cyclophilin inhibitor from an HSP90 inhibitor as a selective inhibitor of hepatitis C virus","volume":"7","author":"Beran","year":"2012","journal-title":"PLoS One"},{"key":"10.1016\/j.ejphar.2019.172747_bib11","author":"B\u00f6sl"},{"key":"10.1016\/j.ejphar.2019.172747_bib12","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1016\/j.antiviral.2016.11.023","article-title":"The FDA-approved drug sofosbuvir inhibits Zika virus infection","volume":"137","author":"Bullard-Feibelman","year":"2017","journal-title":"Antivir. Res."},{"key":"10.1016\/j.ejphar.2019.172747_bib13","doi-asserted-by":"crossref","first-page":"1393","DOI":"10.1007\/s40265-016-0633-9","article-title":"Trifluridine\/tipiracil: a review in metastatic colorectal cancer","volume":"76","author":"Burness","year":"2016","journal-title":"Drugs"},{"key":"10.1016\/j.ejphar.2019.172747_bib14","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1002\/med.20221","article-title":"Transporters that translocate nucleosides and structural similar drugs: structural requirements for substrate recognition","volume":"32","author":"Cano-Soldado","year":"2012","journal-title":"Med. Res. Rev."},{"key":"10.1016\/j.ejphar.2019.172747_bib15","doi-asserted-by":"crossref","first-page":"8507","DOI":"10.1002\/chem.200700260","article-title":"Understanding ribonucleotide reductase inactivation by gemcitabine","volume":"13","author":"Cerqueira","year":"2007","journal-title":"Chem. Eur J."},{"key":"10.1016\/j.ejphar.2019.172747_bib16","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1016\/j.antiviral.2018.05.005","article-title":"Innovation and trends in the development and approval of antiviral medicines: 1987\u20132017 and beyond","volume":"155","author":"Chaudhuri","year":"2018","journal-title":"Antivir. Res."},{"key":"10.1016\/j.ejphar.2019.172747_bib17","doi-asserted-by":"crossref","first-page":"1942","DOI":"10.1128\/AAC.06161-11","article-title":"Activity of a novel combined antiretroviral therapy of gemcitabine and decitabine in a mouse model for HIV-1","volume":"56","author":"Clouser","year":"2012","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.ejphar.2019.172747_bib18","doi-asserted-by":"crossref","first-page":"9301","DOI":"10.1128\/JVI.01006-10","article-title":"Exploiting drug repositioning for discovery of a novel HIV combination therapy","volume":"84","author":"Clouser","year":"2010","journal-title":"J. Virol."},{"key":"10.1016\/j.ejphar.2019.172747_bib19","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12977-016-0254-0","article-title":"Dual anti-HIV mechanism of clofarabine","volume":"13","author":"Daly","year":"2016","journal-title":"Retrovirology"},{"key":"10.1016\/j.ejphar.2019.172747_bib20","doi-asserted-by":"crossref","first-page":"11950","DOI":"10.1128\/JVI.01406-09","article-title":"5-Azacytidine can induce lethal mutagenesis in human immunodeficiency virus type 1","volume":"83","author":"Dapp","year":"2009","journal-title":"J. Virol."},{"key":"10.1016\/j.ejphar.2019.172747_bib21","series-title":"Herpesvirus Polymerase Inhibitors, Viral Polymerases","author":"Das","year":"2018"},{"key":"10.1016\/j.ejphar.2019.172747_bib22","doi-asserted-by":"crossref","first-page":"4265","DOI":"10.1021\/acs.jmedchem.8b01610","article-title":"A survey of the structures of US FDA approved combination drugs","volume":"62","author":"Das","year":"2019","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejphar.2019.172747_bib23","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1128\/CMR.00102-15","article-title":"Approved antiviral drugs over the past 50 years","volume":"29","author":"De Clercq","year":"2016","journal-title":"Clin. Microbiol. Rev."},{"key":"10.1016\/j.ejphar.2019.172747_bib24","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1016\/j.bcp.2017.11.023","article-title":"Role of tenofovir alafenamide (TAF) in the treatment and prophylaxis of HIV and HBV infections","volume":"153","author":"De Clercq","year":"2018","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.ejphar.2019.172747_bib25","doi-asserted-by":"crossref","first-page":"1215","DOI":"10.1002\/med.21256","article-title":"Highlights in antiviral drug research: antivirals at the horizon","volume":"33","author":"De Clercq","year":"2013","journal-title":"Med. Res. Rev."},{"key":"10.1016\/j.ejphar.2019.172747_bib26","doi-asserted-by":"crossref","first-page":"93","DOI":"10.3851\/IMP2533","article-title":"Selective anti-herpesvirus agents","volume":"23","author":"De Clercq","year":"2013","journal-title":"Antivir. Chem. Chemother."},{"key":"10.1016\/j.ejphar.2019.172747_bib27","first-page":"253","article-title":"Viruses and viral diseases","author":"De Clercq","year":"2007","journal-title":"Compr. Med. Chem. II"},{"key":"10.1016\/j.ejphar.2019.172747_bib28","doi-asserted-by":"crossref","first-page":"2301","DOI":"10.1016\/j.bcp.2004.07.039","article-title":"Discovery and development of BVDU (brivudin) as a therapeutic for the treatment of herpes zoster","volume":"68","author":"De Clercq","year":"2004","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.ejphar.2019.172747_bib29","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pntd.0007072","article-title":"Yellow fever virus is susceptible to sofosbuvir both in vitro and in vivo","volume":"13","author":"De Freitas","year":"2019","journal-title":"PLoS Neglected Trop. Dis."},{"key":"10.1016\/j.ejphar.2019.172747_bib30","doi-asserted-by":"crossref","first-page":"35324","DOI":"10.1074\/jbc.M112.392142","article-title":"Obatoclax, saliphenylhalamide, and gemcitabine inhibit influenza A virus infection","volume":"287","author":"Denisova","year":"2012","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.ejphar.2019.172747_bib31","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/1743-422X-9-1","article-title":"Antiretroviral activity of 5-azacytidine during treatment of a HTLV-1 positive myelodysplastic syndrome with autoimmune manifestations","volume":"9","author":"Diamantopoulos","year":"2012","journal-title":"Virol. J."},{"key":"10.1016\/j.ejphar.2019.172747_bib32","doi-asserted-by":"crossref","first-page":"4885","DOI":"10.1128\/AAC.03036-14","article-title":"Repurposing of clinically developed drugs for treatment of Middle East respiratory syndrome coronavirus infection","volume":"58","author":"Dyall","year":"2014","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.ejphar.2019.172747_bib33","first-page":"5716","article-title":"Selectivity of action of an antiherpetic agent, 9-(2-hydroxyethoxymethyl)guanine (antiviral chemotherapy\/virus-specified thymidine kinase\/herpes simplex virus\/virus-specified DNA polymerase\/acycloguanosine triphosphate)","volume":"74","author":"Elion","year":"1977","journal-title":"Med. Sci."},{"key":"10.1016\/j.ejphar.2019.172747_bib34","doi-asserted-by":"crossref","first-page":"1337","DOI":"10.1016\/S0140-6736(80)91790-0","article-title":"Antiviral treatment of VaricellaZoster and herpes simplex","volume":"315","author":"Essmann","year":"1980","journal-title":"Lancet"},{"key":"10.1016\/j.ejphar.2019.172747_bib35","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.01389-18","article-title":"Beyond members of the Flaviviridae family, sofosbuvir also inhibits chikungunya virus replication","volume":"63","author":"Ferreira","year":"2019","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.ejphar.2019.172747_bib36","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1016\/j.bbmt.2011.09.007","article-title":"Safety and efficacy of CMX001 as salvage therapy for severe adenovirus infections in immunocompromised patients","volume":"18","author":"Florescu","year":"2012","journal-title":"Biol. Blood Marrow Transplant."},{"key":"10.1016\/j.ejphar.2019.172747_bib37","doi-asserted-by":"crossref","first-page":"2142","DOI":"10.1016\/j.bmcl.2016.03.076","article-title":"L-Aspartic and l-glutamic acid ester-based ProTides of anticancer nucleosides: synthesis and antitumoral evaluation","volume":"26","author":"Gao","year":"2016","journal-title":"Bioorg. Med. Chem. Lett"},{"key":"10.1016\/j.ejphar.2019.172747_bib38","doi-asserted-by":"crossref","first-page":"1349","DOI":"10.1007\/s00432-011-1005-1","article-title":"RP101 (Brivudine) binds to heat shock protein HSP27 (HSPB1) and enhances survival in animals and pancreatic cancer patients","volume":"137","author":"Heinrich","year":"2011","journal-title":"J. Cancer Res. Clin. Oncol."},{"key":"10.1016\/j.ejphar.2019.172747_bib39","first-page":"4417","article-title":"Evaluation of the antitumor activity of gemcitabine (2 \u2032 , 2 \u2032 evaluation of the antitumor activity of gemcitabine","volume":"50","author":"Hertel","year":"1990","journal-title":"Cancer Res."},{"key":"10.1016\/j.ejphar.2019.172747_bib40","doi-asserted-by":"crossref","first-page":"1224","DOI":"10.1016\/j.drudis.2019.04.006","article-title":"Expanding the activity spectrum of antiviral agents","volume":"24","author":"Ianevski","year":"2019","journal-title":"Drug Discov. Today"},{"key":"10.1016\/j.ejphar.2019.172747_bib41","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1016\/j.antiviral.2018.04.016","article-title":"Novel activities of safe-in-human broad-spectrum antiviral agents","volume":"154","author":"Ianevski","year":"2018","journal-title":"Antivir. Res."},{"key":"10.1016\/j.ejphar.2019.172747_bib42","doi-asserted-by":"crossref","first-page":"H2622","DOI":"10.1152\/ajpheart.00190.2012","article-title":"Prevention of heart failure in mice by an antiviral agent that inhibits type 5 cardiac adenylyl cyclase","volume":"302","author":"Iwatsubo","year":"2012","journal-title":"Am. J. Physiol. Cell Physiol."},{"key":"10.1016\/j.ejphar.2019.172747_bib43","doi-asserted-by":"crossref","first-page":"1436","DOI":"10.1001\/archopht.1986.01050220030009","article-title":"BW B759U for cytomegalovirus retinitis: intraocular drug penetration","volume":"104","author":"Jabs","year":"1986","journal-title":"Arch. Ophthalmol."},{"key":"10.1016\/j.ejphar.2019.172747_bib44","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1016\/j.ijantimicag.2012.01.019","article-title":"Gemcitabine is active against clinical multiresistant Staphylococcus aureus strains and is synergistic with gentamicin","volume":"39","author":"Jordheim","year":"2012","journal-title":"Int. J. Antimicrob. Agents"},{"key":"10.1016\/j.ejphar.2019.172747_bib45","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1038\/nrd4010","article-title":"Advances in the development of nucleoside and nucleotide analogues for cancer and viral diseases","volume":"12","author":"Jordheim","year":"2013","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.ejphar.2019.172747_bib46","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1016\/j.antiviral.2016.11.003","article-title":"Efficacy of the broad-spectrum antiviral compound BCX4430 against Zika virus in cell culture and in a mouse model","volume":"137","author":"Julander","year":"2017","journal-title":"Antivir. Res."},{"key":"10.1016\/j.ejphar.2019.172747_bib47","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1634\/theoncologist.10-3-176","article-title":"FDA drug approval summary: azacitidine (5-azacytidine, Vidaza) for injectable suspension","volume":"10","author":"Kaminskas","year":"2005","journal-title":"The Oncologist"},{"key":"10.1016\/j.ejphar.2019.172747_bib48","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.antiviral.2015.10.011","article-title":"Synergistic antiviral activity of gemcitabine and ribavirin against enteroviruses","volume":"124","author":"Kang","year":"2015","journal-title":"Antivir. Res."},{"key":"10.1016\/j.ejphar.2019.172747_bib49","series-title":"Antiviral Agents. Principles and Practice of Pediatric Infectious Diseases","author":"Kimberlin","year":"2018"},{"key":"10.1016\/j.ejphar.2019.172747_bib50","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/j.antiviral.2016.12.022","article-title":"Obatoclax, saliphenylhalamide and gemcitabine inhibit Zika virus infection in vitro and differentially affect cellular signaling, transcription and metabolism","volume":"139","author":"Kuivanen","year":"2017","journal-title":"Antivir. Res."},{"key":"10.1016\/j.ejphar.2019.172747_bib51","doi-asserted-by":"crossref","first-page":"e24","DOI":"10.1111\/j.1432-2277.2009.01045.x","article-title":"Epstein-Barr virus encephalitis after kidney transplantation and successful treatment with brivudine","volume":"23","author":"Lahmer","year":"2010","journal-title":"Transpl. Int."},{"key":"10.1016\/j.ejphar.2019.172747_bib52","doi-asserted-by":"crossref","first-page":"3359","DOI":"10.1128\/AAC.00054-12","article-title":"Genotype and subtype profiling of PSI-7977 as a nucleotide inhibitor of hepatitis C virus","volume":"56","author":"Lam","year":"2012","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.ejphar.2019.172747_bib53","doi-asserted-by":"crossref","first-page":"1241","DOI":"10.1001\/archinte.1984.00350180181025","article-title":"Acyclovir: pharmacology and clinical experience","volume":"144","author":"Laskin","year":"1984","journal-title":"Arch. Intern. Med."},{"key":"10.1016\/j.ejphar.2019.172747_bib54","doi-asserted-by":"crossref","first-page":"115315","DOI":"10.18632\/oncotarget.23258","article-title":"Gemcitabine, a broad-spectrum antiviral drug, suppresses enterovirus infections through innate immunity induced by the inhibition of pyrimidine biosynthesis and nucleotide depletion","volume":"8","author":"Lee","year":"2017","journal-title":"Oncotarget"},{"key":"10.1016\/j.ejphar.2019.172747_bib55","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1007\/s40121-018-0210-5","article-title":"HIV, HCV and HBV: a review of parallels and differences","volume":"7","author":"Leoni","year":"2018","journal-title":"Infect. Dis. Ther."},{"key":"10.1016\/j.ejphar.2019.172747_bib56","doi-asserted-by":"crossref","first-page":"971","DOI":"10.1128\/AAC.27.6.971","article-title":"Comparative efficacy and selectivity of some nucleoside analogs against Epstein-Barr virus","volume":"27","author":"Lin","year":"1985","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.ejphar.2019.172747_bib57","first-page":"295","article-title":"Deoxyribonucleic acid viruses: antivirals for herpesviruses and hepatitis B virus","author":"Littler","year":"2007","journal-title":"Compr. Med. Chem. II"},{"key":"10.1016\/j.ejphar.2019.172747_bib58","doi-asserted-by":"crossref","first-page":"1153","DOI":"10.1080\/17474124.2018.1530986","article-title":"Improvements in the management of chronic hepatitis B virus infection","volume":"12","author":"Liu","year":"2018","journal-title":"Expert Rev. Gastroenterol."},{"key":"10.1016\/j.ejphar.2019.172747_bib59","first-page":"1","article-title":"Global and regional estimates of prevalent and incident herpes simplex virus type 1 infections in 2012","volume":"10","author":"Looker","year":"2015","journal-title":"PLoS One"},{"key":"10.1016\/j.ejphar.2019.172747_bib60","doi-asserted-by":"crossref","first-page":"978","DOI":"10.1177\/106002809603000913","article-title":"Famciclovir for treatment of herpesvirus infections","volume":"30","author":"Luber","year":"1996","journal-title":"Ann. Pharmacother."},{"key":"10.1016\/j.ejphar.2019.172747_bib61","author":"Luczkowiak"},{"key":"10.1016\/j.ejphar.2019.172747_bib62","doi-asserted-by":"crossref","first-page":"13438","DOI":"10.18632\/oncotarget.24412","article-title":"Trifluridine\/tipiracil overcomes the resistance of human gastric 5-fluorouracil-refractory cells with high thymidylate synthase expression","volume":"9","author":"Matsuoka","year":"2018","journal-title":"Oncotarget"},{"key":"10.1016\/j.ejphar.2019.172747_bib63","doi-asserted-by":"crossref","first-page":"1316","DOI":"10.1093\/jac\/dkm376","article-title":"Preclinical development of bicyclic nucleoside analogues as potent and selective inhibitors of varicella zoster virus","volume":"60","author":"Mcguigan","year":"2007","journal-title":"J. Antimicrob. Chemother."},{"key":"10.1016\/j.ejphar.2019.172747_bib64","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.coviro.2014.04.005","article-title":"Nucleoside\/nucleotide analog inhibitors of hepatitis B virus polymerase: mechanism of action and resistance","volume":"8","author":"Men\u00e9ndez-Arias","year":"2014","journal-title":"Curr. Opin. Virol."},{"key":"10.1016\/j.ejphar.2019.172747_bib65","first-page":"1","article-title":"Blocking Zika virus vertical transmission","volume":"8","author":"Mesci","year":"2018","journal-title":"Sci. Rep."},{"key":"10.1016\/j.ejphar.2019.172747_bib66","doi-asserted-by":"crossref","first-page":"34337","DOI":"10.1074\/jbc.M110.161802","article-title":"Mechanism of activation of PSI-7851 and its diastereoisomer PSI-7977","volume":"285","author":"Murakami","year":"2010","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.ejphar.2019.172747_bib67","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1016\/j.jviromet.2009.06.016","article-title":"Detection and identification of U69 gene mutations encoded by ganciclovir-resistant human herpesvirus 6 using denaturing high-performance liquid chromatography","volume":"161","author":"Nakano","year":"2009","journal-title":"J. Virol. Methods"},{"key":"10.1016\/j.ejphar.2019.172747_bib68","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/cddis.2015.172","article-title":"Zidovudine, an anti-viral drug, resensitizes gemcitabine-resistant pancreatic cancer cells to gemcitabine by inhibition of the Akt-GSK3\u03b2-Snail pathway","volume":"6","author":"Namba","year":"2015","journal-title":"Cell Death Dis."},{"key":"10.1016\/j.ejphar.2019.172747_bib69","doi-asserted-by":"crossref","first-page":"528","DOI":"10.2165\/00003495-199448040-00004","article-title":"Recognition and treatment of shingles","volume":"48","author":"Nikkeis","year":"1994","journal-title":"Drugs"},{"key":"10.1016\/j.ejphar.2019.172747_bib70","doi-asserted-by":"crossref","first-page":"233","DOI":"10.2165\/00003495-198937030-00002","article-title":"Acyclovir: an updated review of its antiviral activity, pharmacokinetic properties and therapeutic efficacy","volume":"37","author":"O'Brien","year":"1989","journal-title":"Drugs"},{"key":"10.1016\/j.ejphar.2019.172747_bib71","author":"Ostrosky-Zeichner"},{"key":"10.1016\/j.ejphar.2019.172747_bib72","doi-asserted-by":"crossref","first-page":"10","DOI":"10.3390\/cancers10060197","article-title":"Antiviral drugs for EBV","volume":"10","author":"Pagano","year":"2018","journal-title":"Cancers"},{"key":"10.1016\/j.ejphar.2019.172747_bib73","doi-asserted-by":"crossref","first-page":"2726","DOI":"10.1128\/AAC.05983-11","article-title":"First pharmacokinetic and safety study in humans of the novel lipid antiviral conjugate CMX001, a broad-spectrum oral drug active against double-stranded DNA viruses","volume":"56","author":"Painter","year":"2012","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.ejphar.2019.172747_bib74","doi-asserted-by":"crossref","first-page":"2880","DOI":"10.1021\/cr900028p","article-title":"Enzymology of purine and pyrimidine antimetabolites used in the treatment of cancer","volume":"109","author":"Parker","year":"2009","journal-title":"Chem. Rev."},{"key":"10.1016\/j.ejphar.2019.172747_bib75","doi-asserted-by":"crossref","first-page":"3584","DOI":"10.1128\/JVI.03483-14","article-title":"Effective lethal mutagenesis of influenza virus by three nucleoside analogs","volume":"89","author":"Pauly","year":"2015","journal-title":"J. Virol."},{"key":"10.1016\/j.ejphar.2019.172747_bib76","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1128\/AAC.00615-10","article-title":"Resistance of herpes simplex viruses to nucleoside analogues: mechanisms, prevalence, and management","volume":"55","author":"Piret","year":"2011","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.ejphar.2019.172747_bib77","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1016\/j.coviro.2011.10.015","article-title":"Progress in the development of new therapies for herpesvirus infections","volume":"1","author":"Price","year":"2011","journal-title":"Curr. Opin. Virol."},{"key":"10.1016\/j.ejphar.2019.172747_bib78","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1016\/0006-3002(59)90597-9","article-title":"Synthesis and biological activities of iododeoxyuridine, an analog of thymidine","volume":"32","author":"Prusoff","year":"1959","journal-title":"BBA - Biochim. Biophys. Acta"},{"key":"10.1016\/j.ejphar.2019.172747_bib79","doi-asserted-by":"crossref","first-page":"1492","DOI":"10.1086\/656717","article-title":"Efficacy of CMX001 against herpes simplex virus infections in mice and correlations with drug distribution studies","volume":"202","author":"Quenelle","year":"2010","journal-title":"J. Infect. Dis."},{"key":"10.1016\/j.ejphar.2019.172747_bib80","doi-asserted-by":"crossref","first-page":"3217","DOI":"10.1038\/s41419-017-0024-5","article-title":"Decitabine, a DNA-demethylating agent, promotes differentiation via NOTCH1 signaling and alters immune-related pathways in muscle-invasive bladder cancer","volume":"8","author":"Ramakrishnan","year":"2017","journal-title":"Cell Death Dis."},{"key":"10.1016\/j.ejphar.2019.172747_bib81","doi-asserted-by":"crossref","first-page":"7222","DOI":"10.1016\/j.bmc.2013.08.023","article-title":"5,6-Dihydro-5-aza-2\u2032-deoxycytidine potentiates the anti-HIV-1 activity of ribonucleotide reductase inhibitors","volume":"21","author":"Rawson","year":"2013","journal-title":"Bioorg. Med. Chem."},{"key":"10.1016\/j.ejphar.2019.172747_bib82","doi-asserted-by":"crossref","first-page":"2318","DOI":"10.1128\/AAC.03084-15","article-title":"5-Azacytidine enhances the mutagenesis of HIV-1 by reduction to 5-aza-2\u2032-deoxycytidine","volume":"60","author":"Rawson","year":"2016","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.ejphar.2019.172747_bib83","doi-asserted-by":"crossref","first-page":"2410","DOI":"10.1016\/j.bmc.2016.03.052","article-title":"Synergistic reduction of HIV-1 infectivity by 5-azacytidine and inhibitors of ribonucleotide reductase","volume":"24","author":"Rawson","year":"2016","journal-title":"Bioorg. Med. Chem."},{"key":"10.1016\/j.ejphar.2019.172747_bib84","doi-asserted-by":"crossref","first-page":"712","DOI":"10.1002\/hep.27323","article-title":"Immunological aspects of antiviral therapy of chronic hepatitis B virus and hepatitis C virus infections","volume":"61","author":"Rehermann","year":"2015","journal-title":"Hepatology"},{"key":"10.1016\/j.ejphar.2019.172747_bib85","first-page":"1691","article-title":"An update on the treatment options for HBV\/HCV coinfection","volume":"18","author":"Sagnelli","year":"2017","journal-title":"Expert Opin. Pharmacother."},{"key":"10.1016\/j.ejphar.2019.172747_bib86","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1093\/jac\/dkm240","article-title":"Nucleoside analogues are activated by bacterial deoxyribonucleoside kinases in a species-specific manner","volume":"60","author":"Sandrini","year":"2007","journal-title":"J. Antimicrob. Chemother."},{"key":"10.1016\/j.ejphar.2019.172747_bib87","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1038\/272583a0","article-title":"9-(2-Hydroxyethoxymethyl) guanine activity against viruses of the herpes group","volume":"272","author":"Schaeffer","year":"1978","journal-title":"Nature"},{"key":"10.1016\/j.ejphar.2019.172747_bib88","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1016\/j.bcp.2013.12.025","article-title":"Vidarabine is neither a potent nor a selective AC5 inhibitor","volume":"87","author":"Seifert","year":"2014","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.ejphar.2019.172747_bib89","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1016\/j.antiviral.2018.04.004","article-title":"The evolution of nucleoside analogue antivirals: a review for chemists and non-chemists. Part 1: early structural modifications to the nucleoside scaffold","volume":"154","author":"Seley-Radtke","year":"2018","journal-title":"Antivir. Res."},{"key":"10.1016\/j.ejphar.2019.172747_bib90","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s13027-017-0128-7","article-title":"The effects of antiviral treatment on breast cancer cell line","volume":"12","author":"Shaimerdenova","year":"2017","journal-title":"Infect. Agents Cancer"},{"key":"10.1016\/j.ejphar.2019.172747_bib91","doi-asserted-by":"crossref","first-page":"211","DOI":"10.3390\/v10040211","article-title":"Gemcitabine and nucleos(t)ide synthesis inhibitors are broad-spectrum antiviral drugs that activate innate immunity","volume":"10","author":"Shin","year":"2018","journal-title":"Viruses"},{"key":"10.1016\/j.ejphar.2019.172747_bib92","doi-asserted-by":"crossref","first-page":"7202","DOI":"10.1021\/jm100863x","article-title":"Discovery of a luoro-2\u2032-\u03b2- C -methyluridine Nucleotide Prodrug (PSI-7977) for the treatment of hepatitis C virus","volume":"53","author":"Sofia","year":"2010","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejphar.2019.172747_bib93","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1016\/j.antiviral.2017.07.003","article-title":"Antiviral activity of gemcitabine against human rhinovirus in vitro and in vivo","volume":"145","author":"Song","year":"2017","journal-title":"Antivir. Res."},{"key":"10.1016\/j.ejphar.2019.172747_bib94","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1002\/ijc.23607","article-title":"Modes of action of the DNA methyltransferase inhibitors azacytidine and decitabine","volume":"123","author":"Stresemann","year":"2008","journal-title":"Int. J. Cancer"},{"key":"10.1016\/j.ejphar.2019.172747_bib95","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1002\/(SICI)1520-6017(200006)89:6<781::AID-JPS10>3.0.CO;2-7","article-title":"Transport of valganciclovir, a ganciclovir prodrug, via peptide transporters PEPT1 and PEPT2","volume":"89","author":"Sugawara","year":"2000","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/j.ejphar.2019.172747_bib96","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1186\/1471-2180-13-184","article-title":"Inhibition of Mycoplasma pneumoniae growth by FDA-approved anticancer and antiviral nucleoside and nucleobase analogs","volume":"13","author":"Sun","year":"2013","journal-title":"BMC Microbiol."},{"key":"10.1016\/j.ejphar.2019.172747_bib97","doi-asserted-by":"crossref","first-page":"1555","DOI":"10.1128\/AAC.42.7.1555","article-title":"Famciclovir and valaciclovir differ in the prevention of herpes simplex virus type 1 latency in mice: a quantitative study","volume":"42","author":"Thackray","year":"1998","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.ejphar.2019.172747_bib98","series-title":"Vidarabine. Ref. Modul. Biomed. Sci.","volume":"1\u20135","author":"Theobald","year":"2016"},{"key":"10.1016\/j.ejphar.2019.172747_bib99","doi-asserted-by":"crossref","first-page":"952","DOI":"10.3389\/fmicb.2019.00952","article-title":"Nucleoside analogues as antibacterial agents","volume":"10","author":"Thomson","year":"2019","journal-title":"Front. Microbiol."},{"key":"10.1016\/j.ejphar.2019.172747_bib100","first-page":"9530","article-title":"Distribution and effects of amino acid changes in drug-resistant \u03b1 and \u03b2 herpesviruses DNA polymerase","volume":"44","author":"Topalis","year":"2016","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.ejphar.2019.172747_bib101","doi-asserted-by":"crossref","first-page":"89","DOI":"10.7326\/0003-4819-123-2-199507150-00002","article-title":"Famciclovir for the treatment of acute herpes zoster: effects on acute disease and postherpetic neuralgia. A randomized, double-blind, placebo- controlled trial","volume":"123","author":"Tyring","year":"1995","journal-title":"Ann. Intern. Med."},{"key":"10.1016\/j.ejphar.2019.172747_bib102","doi-asserted-by":"crossref","first-page":"818","DOI":"10.1002\/ehf2.12341","article-title":"Telbivudine in chronic lymphocytic myocarditis and human parvovirus B19 transcriptional activity","volume":"5","author":"Van Linthout","year":"2018","journal-title":"ESC Hear. Fail."},{"key":"10.1016\/j.ejphar.2019.172747_bib103","doi-asserted-by":"crossref","first-page":"H1","DOI":"10.1152\/ajpheart.00080.2013","article-title":"Adenylyl cyclase type 5 in cardiac disease, metabolism, and aging","volume":"305","author":"Vatner","year":"2013","journal-title":"Am. J. Physiol. Cell Physiol."},{"key":"10.1016\/j.ejphar.2019.172747_bib104","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1038\/clpt.1993.196","article-title":"Pharmacolunetics of the acvclovir pro- drug valaciclovir after iscalati and multiple-dose adrninis tration normal volunteers","author":"Weller","year":"1993","journal-title":"Clin. Pharmacol. Ther."},{"key":"10.1016\/j.ejphar.2019.172747_bib105","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/j.antiviral.2018.05.013","article-title":"Galidesivir limits Rift Valley fever virus infection and disease in Syrian golden hamsters","volume":"156","author":"Westover","year":"2018","journal-title":"Antivir. Res."},{"key":"10.1016\/j.ejphar.2019.172747_bib106","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12964-017-0168-z","article-title":"The double-edged sword of (re)expression of genes by hypomethylating agents: from viral mimicry to exploitation as priming agents for targeted immune checkpoint modulation","volume":"15","author":"Wolff","year":"2017","journal-title":"Cell Commun. Signal."},{"key":"10.1016\/j.ejphar.2019.172747_bib107","series-title":"Global Hepatitis Report, 2017","author":"World Health Organization","year":"2017"},{"key":"10.1016\/j.ejphar.2019.172747_bib108","first-page":"1","article-title":"Evaluation of Sofosbuvir (\u03b2-D-2\u2032-deoxy-2\u2032-\u03b1-fluoro-2\u2032-\u03b2-C-methyluridine) as an inhibitor of Dengue virus replication","volume":"7","author":"Xu","year":"2017","journal-title":"Sci. Rep."},{"key":"10.1016\/j.ejphar.2019.172747_bib109","first-page":"1","article-title":"Comparison of famciclovir, valaciclovir, and brivudine treatments in adult immunocompetent patients with herpes zoster","volume":"9","author":"Yaldiz","year":"2016","journal-title":"Am. J. Therapeut."},{"key":"10.1016\/j.ejphar.2019.172747_bib110","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1016\/j.jconrel.2013.06.009","article-title":"Turning an antiviral into an anticancer drug: nanoparticle delivery of acyclovir monophosphate","volume":"170","author":"Yao","year":"2013","journal-title":"J. Control. Release"},{"key":"10.1016\/j.ejphar.2019.172747_bib111","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1016\/j.antiviral.2018.11.016","article-title":"The evolution of antiviral nucleoside analogues: a review for chemists and non-chemists. Part II: complex modifications to the nucleoside scaffold","volume":"162","author":"Yates","year":"2019","journal-title":"Antivir. Res."},{"key":"10.1016\/j.ejphar.2019.172747_bib112","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1021\/acsinfecdis.6b00116","article-title":"Cell-based high-throughput screening assay identifies 2\u2032,2\u2032- difluoro-2\u2032-deoxycytidine gemcitabine as a potential antipoliovirus agent","volume":"3","author":"Zhang","year":"2017","journal-title":"ACS Infect. Dis."}],"container-title":["European Journal of Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0014299919306995?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0014299919306995?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,15]],"date-time":"2025-09-15T22:32:42Z","timestamp":1757975562000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0014299919306995"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,12]]},"references-count":112,"alternative-id":["S0014299919306995"],"URL":"https:\/\/doi.org\/10.1016\/j.ejphar.2019.172747","relation":{},"ISSN":["0014-2999"],"issn-type":[{"value":"0014-2999","type":"print"}],"subject":[],"published":{"date-parts":[[2019,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Selected nucleos(t)ide-based prescribed drugs and their multi-target activity","name":"articletitle","label":"Article Title"},{"value":"European Journal of Pharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejphar.2019.172747","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"172747"}}